Biotransformation of proteratogenic anti-epileptics in the zebrafish embryo

02:573 years ago

The zebrafish (Danio rerio) embryo has gained interest as an alternative model for developmental toxicity testing, which still mainly relies on in vivo mammalian models (e.g., rat, rabbit). However, cytochrome P450 (CYP)-mediated drug metabolism, which is critical for the bioactivation of several proteratogens, is still under debate for this model. Therefore, we investigated the potential capacity of zebrafish embryos/larvae to bioactivate two known mammalian proteratogens, carbamazepine (CBZ) and phenytoin (PHE) into their mammalian active metabolites, carbamazepine-10,11-epoxide (E-CBZ) and 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH), respectively. Zebrafish embryos were exposed to three concentrations (31.25, 85, and 250 μM) of CBZ and PHE from 51⁄4 to 120 hours post fertilization (hpf) at 28.5°C under a 14/10 hour light/dark cycle. For species comparison, also adult zebrafish, rat, rabbit and human liver microsomes (200 μg/ml) were exposed to 100 μM of CBZ or PHE for 240 minutes at 28.5°C. Potential formation of the mammalian metabolites was assessed in the embryo medium (48, 96, and 120 hpf); pooled (n=20) whole embryos/larvae extracts (24 and 120 hpf); and in the microsomal reaction mixtures (at 5 and 240 minutes) by targeted investigation using a UPLC–Triple Quadrupole MS system with lamotrigine (0.39 μM) as internal standard. Our study showed that zebrafish embryos metabolize CBZ to E-CBZ, but only at the end of organogenesis (from 96 hpf onwards), and no biotransformation of PHE to HPPH occurred. In contrast, our in vitro drug metabolism assay showed that adult zebrafish metabolize both compounds into their active mammalian metabolites. However, significant differences in metabolic rate were observed among the investigated species. These results highlight the importance of including the zebrafish in the in vitro drug metabolism testing battery
for accurate species selection in toxicity studies.

Related

TPI.tv: improving science through animal-free innovations and research
TPI.tv videos
InnovationPolicyBeginner

TPI.tv: improving science through animal-free innovations and research

Introducing TPI.tv : a video platform by experts striving to improve science through animal-free innovations and research.
01:264 years ago
Five simple tricks for making your own video for TPI.tv
TPI.tv videos

Five simple tricks for making your own video for TPI.tv

This video shows you how to make a video yourself. It's really not that difficult! See also the submission page (https://tpi.tv/submit-a-video) for additional information.
01:234 years ago
User Research in developing the virtual human platform
Innovation examples
ToxicologyPolicy

User Research in developing the virtual human platform

Digital tools can support the phasing out of animal-based tests and data in chemical risk assessment. This is one of the core promises of the Virtual Human Platform. The potential contribution of digitalization is linked to the acceptance and adoption of tools, methods, and data by stakeholders in several societal sectors. To facilitate the integration of stakeholders in the configuration of digital tools, Dr. Isaac Ortega Alvarado and colleagues gather insights from risk assessors in their role as users. Risk assessors are the ones who actualize chemical risk assessment and its standards through their practices. With this perspective, this research contributes to understanding the development and implementation of digital tools as embedded in social processes of construction and reception.
01:156 days ago
NXTGEN Hightech Biomed
Projects and initiatives
HealthInnovationIn vitroOrgan-on-Chip

NXTGEN Hightech Biomed

The Netherlands has strong academic knowledge in areas like Lab-on-Chip, Organ-on-Chip, artificial organs, and cell production technology. However, turning this knowledge into actual products is challenging due to the need for collaboration between different technological and biological specialists. The NXTGEN Hightech program (https://nxtgenhightech.nl/en/biomed/) addresses this by creating a collaborative environment where companies from various fields work together. This approach aims to transform academic insights into innovative products, benefiting both the industry and society.
02:177 days ago